Two University Hospitals Physician-Scientists to Receive 2024 Top Ten Clinical Research Achievement Awards from the Clinical Research Forum

Two University Hospitals physician-scientists will receive recognition for their profound contributions to advancing clinical research. UH is the only hospital system to have two honorees acknowledged this year by the Clinical Research Forum for the 10 most significant clinical advancements impacting the health and wellness of humanity.

Large Multicenter Clinical Trial Finds that Antiseptic Containing Iodine Reduces Surgical-Site Infections in Patients with Extremity Fractures

A large multicenter clinical trial co-led by University of Maryland School of Medicine researchers found that an antiseptic containing iodine resulted in about one-quarter fewer post-surgical infections in patients with limb fractures compared to another frequently used skin antiseptic.

New findings offer improved therapy of early-stage, BRCA mutation-associated breast cancer

Results were released this week on a new treatment with the potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a drug that blocks cancer cells from repairing their DNA (called a PARP inhibitor) has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy.

Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations

The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.